Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $467K invested in Phio Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
21% more capital invested
Capital invested by funds: $387K → $467K (+$80.1K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.14% less ownership
Funds ownership: 3.43% → 3.29% (-0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.08K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$2.28K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$940 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$924 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$34K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$8K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$1.84K |
| 4 |
MYIA
Mount Yale Investment Advisors
Denver,
Colorado
|
-$63 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $217K | +$88.7K | +38,963 | +80% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $144K | +$483 | +212 | +0.4% |
|
|
3
Cetera Investment Advisers
Schaumburg,
Illinois
| $83.1K | +$2.28K | +1,000 | +3% |
|
4
Morgan Stanley
New York
| $14.9K | – | – | – |
|
|
5
Bank of America
Charlotte,
North Carolina
| $3.47K | +$3.08K | +1,354 | +2,943% |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $2.73K | -$1.84K | -808 | -42% |
|
|
7
BNP Paribas Financial Markets
Paris,
France
| $1.02K | +$940 | +413 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1.01K | +$924 | +406 | New |
|
9
AssetMark Inc
Concord,
California
| $273 | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $32 | +$30 | +13 | New |
|
|
AWM
11
Activest Wealth Management
Aventure,
Florida
| $22 | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$34K | -14,298 | Closed |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$8K | -3,464 | Closed |
|
|
MYIA
14
Mount Yale Investment Advisors
Denver,
Colorado
| – | -$63 | -27 | Closed |
|
PHIO Hedge Fund Activity: Q3 2025 in Review
11 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2025, worth a combined $467K — up 21% from $387K a quarter earlier.
Fund positioning in PHIO was balanced in Q3 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $88.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $34K sold.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $467K of Phio Pharmaceuticals stock for Q3 2025, up 21% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q3 2025 and 3 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $88.7K added.
- The largest Phio Pharmaceuticals seller in Q3 2025 was Virtu Financial, an estimated $34K sold.
Based on aggregated 13F filings for Q3 2025.